DocWire News Editors

DocwireNews

A new granulocyte-colony stimulating factor biosimilar demonstrated therapeutic equivalence to a reference brand of pegfilgrastim (Neulasta&reg;, Amgen) for use in patients with <a href="https://proddocwire.wpengine.com/docwire-pick/hem-onc-picks/breast-cancer-deaths-averted-screening/">breast cancer</a> receiving chemotherapy, according to results from a recent study.The authors, publishing in BMC Cancer, noted in their background section that biosimilars for a related therapy, filgrastim (approved in 1991), had been approved in Europe since 2009 and in the United States in 2015, but that biosimilars for pegfilgrastim are still in various stages of development. The present study looked at proposed biosimilar RGB-02 (Gedeon Richter) in comparison to Neulasta (approved in 2002) in a double-blind clinical trial setting.The study was conducted across 35 centers located in Hungary, Romania, Russia, Ukraine, Serbia, Croatia, Bulgaria, and Czech Republic between January 2014 and April 2015. The randomized, double-blind, phase III clinical study included 239 women, who were randomized (1:1) to receive either RGB-02 (n=121) or the reference product (n=118). The study population was limited to chemotherapy-na&iuml;ve women between 18 and 65 with invasive Stage IIB and III breast cancer. Patients were assigned to up to six cycles of docetaxel (60 mg/m2)/doxorubicin (75 mg/m2) chemotherapy as myelosuppressive chemotherapy combination, as well as a once-per-cycle injection of pegfilgrastim (6 mg).The primary study endpoint was the duration of severe neutropenia (absolute neutrophil count [ANC] &lt; 0.5 &times; 109/L) in Cycle 1, with secondary endpoints of severe neutropenia incidence and duration, incidence of febrile neutropenia, time to ANC recovery, and depth of ANC nadir in Cycles 1 and 2.According to the results, RGB-02 demonstrated therapeutic equivalence with the reference pegfilgrastim. The mean duration of severe neutropenia in Cycle 1 and Cycle 2 was comparable between the two study groups. The researchers also reported no statistically significant differences in secondary endpoints between study groups, and no clinically relevant differences either. The incidence and duration of severe neutropenia and episodes fever and treatment with antibiotics were &ldquo;almost identical in both groups, according to the authors.&ldquo;The mean duration of severe neutropenia in Cycles 3 and 4, after patients in the reference arm switched to RGB-02, was less than one day in the RGB-02 arm (0.9 days) and the reference arm switched to RGB-02 (0.6 days), indicating that the switch from reference to RGB-02 treatment did not increase the patient&rsquo;s risk to develop longer lasting grade 4 neutropenia,&rdquo; they wrote.The safety profile suggested equivalence, with similar numbers of adverse events occurring in both study groups. Two deaths were reported in the RBG-02 arm but were unrelated to the investigational medication.&ldquo;The safety profile of RGB-02 is comparable with the reference pegfilgrastim and no immunogenicity was found, even after switching from the originator product to RGB-02,&rdquo; the researchers added in the study. &ldquo;The incidence and severity of bone pain associated with the use of pegfilgrastim was comparable between treatment arms and was similar to previous studies.&rdquo;The researchers also looked at immunogenicity, which they noted could occasionally cause problems for biologics if the body produces antidrug antibodies leading to a loss of efficacy or to adverse reactions. The screening assay test was negative in 96.1% of immunogenicity samples for the double-blind treatment period. The results, the authors said, suggested no immunogenic responses to the study drug and no detection of anti-pegfilgrastim antibodies during the study period.Read more at BMC Cancer (<a href="https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5329-6">https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5329-6</a>)

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

Pegfilgrastim Biosimilar Shows Therapeutic Equivalence to Neulasta

Breast Cancer News

A new granulocyte-colony stimulating factor biosimilar demonstrated therapeutic equivalence to a reference brand of pegfilgrastim (Neulasta®, Amgen) for use in patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe